Individualized dosing of tyrosine kinase inhibitors: are we there yet?
D de Wit, HJ Guchelaar, J den Hartigh… - Drug discovery today, 2015 - Elsevier
Highlights•Complete overview on exposure–response relationships for TKIs used in solid
tumors.•Dose individualization is expected to minimize toxicity and improve efficacy.•For …
tumors.•Dose individualization is expected to minimize toxicity and improve efficacy.•For …
Small molecule kinase inhibitors as anti-cancer therapeutics
O Chahrour, D Cairns, Z Omran - Mini reviews in medicinal …, 2012 - ingentaconnect.com
Protein kinases have emerged as the most important class of targets in oncology drug
discovery because of their major roles in regulating cellular growth and survival. At least, 11 …
discovery because of their major roles in regulating cellular growth and survival. At least, 11 …
Efficacy of Erlotinib plus dendritic cells and cytokine-induced killer cells in maintenance therapy of advanced non–small cell lung Cancer
SB Shi, XY Tang, J Tian, CX Chang, P Li… - Journal of …, 2014 - journals.lww.com
The aim of this study was to evaluate the safety and effectiveness of erlotinib plus DC/CIK in
maintenance therapy of advanced non–small cell lung cancer. After 4 cycles of the 2-drug …
maintenance therapy of advanced non–small cell lung cancer. After 4 cycles of the 2-drug …
肺癌的中医药维持治疗思路
侯炜， 王兵， 颜琳琳 - 中医杂志, 2014 - cqvip.com
随着现代化学治疗模式在肿瘤治疗领域的不断发展, 维持治疗越来越受到重视,
但也存在毒副作用较多, 过度治疗, 费用偏高等弊端. 中医药在长期稳定瘤体, 防止复发转移 …
但也存在毒副作用较多, 过度治疗, 费用偏高等弊端. 中医药在长期稳定瘤体, 防止复发转移 …
Erlotinib and pemetrexed as maintenance therapy for advanced non-small-cell lung cancer: a systematic review and indirect comparison
Background: Two new agents have recently been licensed as maintenance therapy for
advanced non-small-cell lung cancer (NSCLC) by the US Food and Drug Administration …
advanced non-small-cell lung cancer (NSCLC) by the US Food and Drug Administration …
益气养阴法维持治疗非小细胞肺癌
田静， 肖军， 吴海良 - 吉林中医药, 2015 - cqvip.com
目的观察益气养阴法维持治疗中晚期非小细胞肺癌的疗效及安全性. 方法入组患者随机分为治疗
组和对照组. 治疗组口服益气养阴中药治疗, 对照组单纯随访. 结果治疗组身体状况评分改善情况 …
组和对照组. 治疗组口服益气养阴中药治疗, 对照组单纯随访. 结果治疗组身体状况评分改善情况 …
非小细胞肺癌分子表型与EGFR-TKI 治疗相关性研究进展
冯雪苹， 宋鑫 - 实用肿瘤杂志, 2012 - cqvip.com
非小细胞肺癌分子表型与EGFR-TKI治疗相关性研究进展-[维普官方网站]-www.cqvip.com-维普
网 我的维普 购物车 充值 客服 首页 | 期刊大全 | 文献分类 | 优先出版 | 论文检测 | 论文选题 …
网 我的维普 购物车 充值 客服 首页 | 期刊大全 | 文献分类 | 优先出版 | 论文检测 | 论文选题 …
[PDF][PDF] Antitumor activity of liposomal formulations oof bis-naphthalimide derivatives and erlotinib, in vitro study in pancreatic cancer cell lines
RIHS Vidal - 2013 - repositorio-aberto.up.pt
Pancreatic cancer (PC) remains one of the most aggressive types of cancer, resulting in a 5
years survival rate of less than 5%, lacking in new therapies that present higher rates of …
years survival rate of less than 5%, lacking in new therapies that present higher rates of …
ROLE OF THE IMMUNE SYSTEM IN TUMOR PROGRESSION
TOHPK BENJAMIN - 2011 - scholarbank.nus.edu.sg
In order to metastasize, cancer cells need to acquire a motile phenotype. Previously,
development of this phenotype was thought to rely on the acquisition of selected, random …
development of this phenotype was thought to rely on the acquisition of selected, random …
[图书][B] Synergistic anticancer activity of arsenic trioxide and the EGFR inhibitor erlotinib
K Kryeziu - 2011 - phaidra.univie.ac.at
Arsenic is considered as the oldest remedy in the world which has been used for more than
2400 years. After rediscovery of anti-leukemic effects in the late 20th century, arsenic trioxide …
2400 years. After rediscovery of anti-leukemic effects in the late 20th century, arsenic trioxide …